Adragos Pharma, a Germany-based global CDMO, has appointed Konstantinos (Kostas) Rengis as its new CEO, succeeding company founder and CEO for the last six years, Dr Andreas Raabe. Raabe will remain a shareholder of Adragos and continue to support the company while shifting his focus from daily operations toward investment activities and advisory support.
Rengis brings extensive international leadership experience across pharmaceutical manufacturing, R&D and CDMO operations, leading organisations across Europe, North America, Latin America and Asia. Most recently, he served as Group CEO of FAMAR.
Since its founding, Adragos has grown into a multinational CDMO operating across six sites in five countries. Dr. Raabe will remain a shareholder of Adragos and continue to support the company while shifting his focus from daily operations toward investment activities and advisory support.
In the company’s next phase, Rengis “will focus on operational execution, consistent delivery, integration of capabilities across the network, and the continued development of our manufacturing, R&D and commercial activities.”
Adragos is backed by FSN Capital, which invested in 2021, and the Prange Family Office.
Press release: Adragos Pharma Appoints Kostas Rengis as Chief Executive Officer
